PRESS RELEASE published on 03/04/2025 at 08:35, 11 months 4 days ago AB Science: Article from the leading publication Life Sciences Magazine featuring masitinib and its Phase 3 principal investigator, the neurologist Patrick Vermersch AB Science's masitinib and its phase 3 principal investigator, neurologist Patrick Vermersch, featured in Life Sciences Magazine for potential breakthrough in Progressive MS Treatment AB Science Masitinib Patrick Vermersch Life Sciences Magazine Progressive MS Treatment
BRIEF published on 01/29/2025 at 19:08, 1 year ago AB Science Updates on Masitinib Platform Progress Multiple Sclerosis Masitinib Platform ALS Study Alzheimer’s Treatment AB Science Strategy
PRESS RELEASE published on 01/29/2025 at 19:03, 1 year ago AB Science today provides an update on its masitinib platform AB Science provides update on masitinib platform for ALS, MS, and AD. Positive results show potential for huge market sales. Debt negotiation planned Update AB Science Masitinib Platform Market Sales Debt Negotiation
BRIEF published on 01/24/2025 at 18:06, 1 year ago AB Science to Present Masitinib Update in Upcoming Webcast Pharmaceuticals Webcast Research Update AB Science Masitinib
PRESS RELEASE published on 01/24/2025 at 18:01, 1 year ago AB Science will host a live webcast on Tuesday January 28, 2025, from 5.30pm to 6.45pm CET AB Science to host live webcast on masitinib platform update on January 28, 2025, 5.30pm CET. Leading pharmaceutical company specializing in protein kinase inhibitors Pharmaceutical Company Live Webcast AB Science Protein Kinase Inhibitors Masitinib Platform
BRIEF published on 01/22/2025 at 19:04, 1 year ago AB Science Participates in Biomed Forum Investors Conference Investor Conference BIOMED Forum AB Science Masitinib Protein Kinase Inhibitors
PRESS RELEASE published on 01/22/2025 at 18:59, 1 year ago AB Science will participate in the Biomed Forum investors conference AB Science to participate in Biomed Forum Investors Conference organized by AllInvest Securities in Paris on February 4, 2025 Pharmaceutical Company BIOMED Forum AB Science Investors Conference AllInvest Securities
BRIEF published on 12/17/2024 at 19:09, 1 year 1 month ago AB Science presents the advances of AB8939 for acute myeloid leukemia Phase 1 AB8939 Acute Myeloid Leukemia Drug Resistance Potential Market
PRESS RELEASE published on 12/17/2024 at 19:04, 1 year 1 month ago AB Science provides a summary of the webcast held on December 16, 2024 AB Science provides an update on AB8939, a novel microtubule destabilizer and ALDH inhibitor in phase 1 for AML treatment. Potential market size exceeded EUR 2 billion per annum Market Potential AML Treatment AB Science Phase 1 AB8939
BRIEF published on 10/17/2024 at 19:33, 1 year 3 months ago AB Science Faces Setback in EMA Approval for ALS Treatment AB Science Masitinib Marketing Authorization ALS Treatment EMA Decision
Published on 02/07/2026 at 01:00, 1 day 10 hours ago Green Bridge Metals Can Help Secure U.S. Production of Critical Mineral Titanium
Published on 02/06/2026 at 23:10, 1 day 12 hours ago Topline Capital Management, LLC Announces Disposition of Shares of NamSys Inc.
Published on 02/06/2026 at 22:01, 1 day 13 hours ago Totec Resources Announces Listing of Shares on the Frankfurt Stock Exchange and Adoption of Omnibus Incentive Plan
Published on 02/06/2026 at 15:30, 1 day 20 hours ago Vulcan Minerals Inc. - Drilling Program Update for the Carbonear Zinc-Lead SEDEX project in Newfoundland
Published on 02/06/2026 at 13:30, 1 day 22 hours ago Redwood AI Corp. (formerly Marshall Technologies Corp.) Announces Closing of IPO and Listing of Shares on the Canadian Securities Exchange
Published on 02/07/2026 at 21:00, 14 hours 30 minutes ago Alibaba Group Debuts 'Wonder on Ice,' an Immersive AI Experience at Milan’s Sforza Castle for Milano Cortina 2026
Published on 02/07/2026 at 16:35, 18 hours 55 minutes ago The Ministry of Finance and the International Monetary Fund to launch tomorrow the second edition of the AlUla Conference for Emerging Market Economies
Published on 02/07/2026 at 16:20, 19 hours 10 minutes ago NOTICE OF SETTLEMENT APPROVAL HEARING - SHORT FORM - WAYLAND GROUP CORP., SCOTT LANGILLE, GERHARD MÜLLER, PAUL PATHAK, ERIC SILVER, MICHAEL STEIN, JOHN DOES 1-3, CANACCORD GENUITY CORP., AND RF SECURITIES CLEARING LP (FORMERLY KNOWN AS GMP SECU
Published on 02/06/2026 at 19:25, 1 day 16 hours ago Funding Circle Holdings plc: POS-Transaction in Own Shares
Published on 02/06/2026 at 17:52, 1 day 17 hours ago EQS-Adhoc: Avemio AG: Preparation of the filing for insolvency proceedings by Teltec AG, a subsidiary of Avemio AG, and potential effects on the going-concern assessment of Avemio AG
Published on 02/06/2026 at 18:22, 1 day 17 hours ago Disclosure of Share Capital and Voting Rights as of January 31, 2026
Published on 02/06/2026 at 16:01, 1 day 19 hours ago Notice of exercise of early redemption option of the subordinated note ISIN : FR0010093328
Published on 02/05/2026 at 18:06, 2 days 17 hours ago Aéroports de Paris SA - Shares and voting rights as of 31 January 2026
